As the blizzard of announcements coming from the White House during Donald Trump's first weeks in office continues, Irish ...

Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

In my last article, I outlined the inflection point facing the pharmaceutical ... the next best action for the company’s sales reps to take. Fonseca joined Pfizer in 2019, bringing more than ...

Texas Attorney General Ken Paxton has launched an investigation into DeepSeek, the upstart Chinese artificial intelligence ...

As advertisers pay more for an ever-scarcer supply of ratings points, pharma’s ironclad devotion to TV could finally be in ...

Casey Fowler considers how intellectual property (IP) management will play a role in protecting pharma companies’ investments ... the US Patent and Trademark Office (USPTO) concluded that ...

We recently published a list of Why Are These 10 Dividend Stocks Declining? In this article, we are going to take a look at ...

DMU will be part of a consortium laying the foundation for future medicines that are affordable, safe, effective, and ...

From Ben Affleck's DunKings to David Beckham and his long-lost twin Dave (played by Matt Damon) and all the pop star ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.

Growing demand for tryptamine APIs stems from their anti-cancer potential, pharmaceutical uses, and role as a neurotransmitter modulator i ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...